News
Check back here regularly to find out what's going on at our company.
August 2021: EbD cofounder Dr. Schalk named as Semifinalist for the AIM-HI Women's Venture Competition
November 2020: EbD cofounder Dr. Schalk received Innovator Award (Early Career) by the Association of Women in Science-Chicago.
September 2020: EbD awarded $2M SBIR Phase II grant to further develop and derisk their innovative safer mammalian asparaginase.
September 2020: EbD awarded SBIR Phase I grant to develop half-life extension version of their safer mammalian asparaginase.
July 2020: Dr. Arnon Lavie of Enzyme by Design featured in Illinois Ventures Q2 2020 Roundup
https://www.illinoisventures.com/news/coffee-with-a-founder-arnon-lavie-of-enzyme-by-design
July 2020: EbD cofounder Dr. Schalk named Scientist of the Month by the Association of Women in Science-Chicago.
http://www.awis-
Photo by Jenny Fontaine - UIC
Photo by Courtney Colvin, UI Cancer Center News
April 2019: Enzyme by Design cofounder Dr. Arnon Lavie wins the MedCity INVEST Biopharma Startup Contest
Chicago, Ill., April 25, 2019 – Yesterday afternoon, Enzyme by Design - a cancer therapeutic startup spun out from the University of Illinois at Chicago - was named the winner of the BioPharma category in the Pitch Perfect Startup contest at MedCity INVEST. This 2-day national conference focuses on healthcare investing in the Midwest and took place at the Ritz-Carlton at Water Tower place in downtown Chicago. Enzyme by Design was one of 43 startups selected to give pitches at this event with technology ranging from therapeutics and diagnostics to medical devices and health IT.
Dr. Arnon Lavie, Enzyme by Design’s CEO, gave an engaging winning pitch on the exciting new cancer therapeutic his team engineered and are currently developing. His passion and commitment to the mission of designing safer oncology treatment options was readily apparent and permeated the room. Through precise enzyme engineering, his team’s biologic drug can selectively starve certain tumor cells of a key nutrient and kill them off without also causing debilitating side effects that plague current FDA-approved variants. Enzyme by Design is excited about finding the right investors who believe in the impact of our mission to develop safe and effective cancer therapeutics. The company is seeking seed funding to complete IND-enabling studies, which will allow for first-in-human trials that will establish its superior safety profile in a Phase I clinical trial.
Credit: MedCity News
Jan 2019: EbD awarded NIH I-corp grant to interview 100 experts and develop a commercialization strategy
Dec 2018: EbD awarded NSF I-corp grant through University of Chicago's Polsky Center for Entrepreneurship and Education
Sept 2018: EbD awarded NIH STTR grant to develop a novel AML biologic drug
July 2018: EbD awarded NIH STTR grant to develop a novel L-asparaginase
Feb 2018: UIC Cancer Center publishes writeup on EbD's CEO
UIC Cancer Center News: UIC Cancer Center publishes writeup on EbD's CEO
Jan 2018: EbD publishes the advantage of low L-glutaminase L-asparaginase in Cancer Research
Print 